Media
Press releases and topics in the spotlight
Welcome to our media section. Check out the latest interviews, news, and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
In the spotlight
CEO Christer Alhberg presents at Redeye Life Science Day 2025
Watch the full presentation by CEO Christer Ahlberg about Cinclus Pharma and the development of linaprazan glurate, presented at Redeye Life Science Day December 3.
Cinclus Pharma invites to KOL event
Cinclus Pharma Holding AB (publ) will host a virtual event featuring Professor Prateek Sharma from the Cancer Center in Kansas City, to provide deeper insights on the current treatment landscape and the unmet medical need among patients with erosive…
Cinclus Pharma’s CEO Christer Ahlberg in an interview with Redeye about the Phase III study and the Q3 report
Redeye has interviewed Cinclus Pharma’s CEO, Christer Ahlberg, about the company’s recently initiated Phase III study with linaprazan glurate and the company’s Q3 report.
Watch the full presentation from Redeye Investor Forum
Here you can watch the full presentation by CEO Christer Ahlberg about Cinclus Pharma and the development of linaprazan glurate, presented at the Redeye Investor Forum
Cinclus Pharma in media
Kjell Andersson in the Lonza Podcast: A View On: Developing Acid Reflux Therapy
2025-03-06Kjell Anderson, Chief Scientific Officer and Founder of Cinclus Pharma, discusses a novel treatment for acid reflux in this episode ‘A View On: Developing Acid Reflux Therapy’ of the Lonza podcast.
Placera.se lists Swedish stocks offering the biggest upside
2025-01-02Cinclus Pharma is on the list of analysts' favorite stocks when Placera.se lists Swedish stocks offering the biggest upside.
Bengt Julander on Cinclus Pharma in DITV
2024-12-11Bengt Julander, Chairman of one of Cinclus Pharma's largest shareholders, Linc, participated in DITV, saying Cinclus Pharma has the world's best stomach ulcer treatment.
Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
2024-11-28Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
Cinclus Pharma's CEO Christer Ahlberg interviewed by Redeye
2024-09-23Cinclus Pharma's CEO Christer Ahlberg was interviewed by Okee Williams at Redeye AB on September 23, about the company and the development of the drug candidate linaprazan glurate.
